Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Update

Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Rating) was the recipient of a significant drop in short interest in April. As of April 15th, there was short interest totalling 26,700 shares, a drop of 58.3% from the March 31st total of 64,000 shares. Based on an average daily trading volume, of 50,200 shares, the short-interest ratio is presently 0.5 days. Currently, 0.4% of the company’s stock are sold short.

CYTH opened at $2.70 on Friday. The company’s 50-day moving average is $3.02 and its 200 day moving average is $4.22. Cyclo Therapeutics has a fifty-two week low of $2.46 and a fifty-two week high of $13.00. The firm has a market capitalization of $17.43 million, a P/E ratio of -1.19 and a beta of -0.93.

Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) last released its quarterly earnings results on Monday, March 14th. The company reported ($0.34) earnings per share for the quarter. Cyclo Therapeutics had a negative net margin of 900.76% and a negative return on equity of 117.23%. The firm had revenue of $0.59 million for the quarter.

In other news, CEO N Scott Fine purchased 10,334 shares of the company’s stock in a transaction that occurred on Monday, February 7th. The shares were bought at an average cost of $3.58 per share, with a total value of $36,995.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Markus Sieger purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 29th. The shares were purchased at an average cost of $2.73 per share, for a total transaction of $27,300.00. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CYTH. Renaissance Technologies LLC lifted its position in shares of Cyclo Therapeutics by 532.5% during the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $247,000 after purchasing an additional 55,818 shares in the last quarter. UBS Group AG increased its holdings in Cyclo Therapeutics by 259.8% during the third quarter. UBS Group AG now owns 39,914 shares of the company’s stock worth $269,000 after buying an additional 28,820 shares during the last quarter. Virtu Financial LLC purchased a new stake in Cyclo Therapeutics during the fourth quarter worth about $83,000. Two Sigma Advisers LP purchased a new stake in Cyclo Therapeutics during the third quarter worth about $82,000. Finally, Geode Capital Management LLC increased its holdings in Cyclo Therapeutics by 20.8% during the third quarter. Geode Capital Management LLC now owns 51,454 shares of the company’s stock worth $347,000 after buying an additional 8,877 shares during the last quarter. 5.15% of the stock is currently owned by institutional investors.

Cyclo Therapeutics Company Profile (Get Rating)

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease.

See Also